Absence of Neisseria Meningitidis Serogroup C-specific Antibodies During the First Year of Life in the Netherlands: an Age Group at Risk?

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2009 Aug 21

PMID 19692627

Authors

Richarda M de Voer

Fiona R M van der Klis

Laetitia E M Niers

Ger T Rijkers

Guy A M Berbers

Affiliations

Soon will be listed here.

Abstract

In The Netherlands, a single meningococcal serogroup C conjugate (MenCC) vaccination is administered to children at the age of 14 months. Here, we report the levels of MenC polysaccharide-specific antibodies in children at birth and at 3, 11, and 12 months of age and the presence of functional antibodies at 11 months of age, before infants receive their MenCC immunization. We observed a rapid decline in polysaccharide-specific antibodies after birth and no induction of naturally elicited polysaccharide-specific antibodies. Furthermore, at 11 months of age, no bactericidal antibodies are observed. These data indicate that these infants may be at risk in the period prior to MenCC immunization, if Neisseria meningitidis serogroup C starts to (re)circulate.

References

Cameron C, Pebody R . Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill. 2006; 11(3):E060302.4. DOI: 10.2807/esw.11.09.02913-en. View

de Voer R, Schepp R, Versteegh F, van der Klis F, Berbers G . Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin Vaccine Immunol. 2009; 16(3):433-6. PMC: 2650869. DOI: 10.1128/CVI.00364-08. View

de Voer R, van der Klis F, Nooitgedagt J, Versteegh F, van Huisseling J, van Rooijen D . Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis. 2009; 49(1):58-64. DOI: 10.1086/599347. View

Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N . Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine. 2007; 25(41):7233-7. DOI: 10.1016/j.vaccine.2007.07.019. View

Snape M, Kelly D, Green B, Moxon E, Borrow R, Pollard A . Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005; 24(2):128-31. DOI: 10.1097/01.inf.0000151029.58752.27. View

Trotter C, Borrow R, Andrews N, Miller E . Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003; 21(11-12):1094-8. DOI: 10.1016/s0264-410x(02)00630-8. View

Trotter C, Borrow R, Findlow J, Holland A, Frankland S, Andrews N . Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008; 15(11):1694-8. PMC: 2583529. DOI: 10.1128/CVI.00279-08. View

Gasparini R, Rizzetto R, Sasso T, Rizzitelli E, Manfredi P, Risso D . Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario. Vaccine. 2009; 27(25-26):3435-8. DOI: 10.1016/j.vaccine.2009.01.076. View

De Greeff S, de Melker H, Spanjaard L, Schouls L, van Derende A . Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006; 25(1):79-80. DOI: 10.1097/01.inf.0000195594.41449.c6. View

10.

ODempsey T, McArdle T, Ceesay S, Secka O, Demba E, Banya W . Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy. Arch Dis Child Fetal Neonatal Ed. 1996; 74(1):F43-6. PMC: 2528317. DOI: 10.1136/fn.74.1.f43. View

11.

De Wals P, Trottier P, Pepin J . Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine. 2006; 24(17):3500-4. DOI: 10.1016/j.vaccine.2006.02.010. View

12.

Miller E, Salisbury D, Ramsay M . Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001; 20 Suppl 1:S58-67. DOI: 10.1016/s0264-410x(01)00299-7. View

13.

Southern J, Borrow R, Andrews N, Morris R, Waight P, Hudson M . Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol. 2008; 16(2):194-9. PMC: 2643544. DOI: 10.1128/CVI.00420-08. View

14.

Wiese-Posselt M, Hellenbrand W, Siedler A, Mayer C . Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany. Euro Surveill. 2006; 11(9):E060907.4. DOI: 10.2807/esw.11.36.03041-en. View

15.

Maiden M, Ibarz-Pavon A, Urwin R, Gray S, Andrews N, Clarke S . Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008; 197(5):737-43. PMC: 6767871. DOI: 10.1086/527401. View

16.

Maslanka S, Gheesling L, Libutti D, Donaldson K, Harakeh H, Dykes J . Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997; 4(2):156-67. PMC: 170495. DOI: 10.1128/cdli.4.2.156-167.1997. View

17.

McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon E . Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002; 21(8):747-53. DOI: 10.1097/00006454-200208000-00010. View